Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.18 USD | -0.87% | +5.76% | -30.37% |
May. 16 | Advanced Oxygen Therapy plans London float - Sky News | AN |
May. 15 | Walgreens to Sell Over-the-Counter Naloxone Anti-Narcotic Spray to Reverse Opioid Overdoses | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The stock, which is currently worth 2024 to 0.16 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.37% | 15.68B | B- | ||
-22.51% | 12.39B | B | ||
-22.88% | 6.74B | B | ||
-6.01% | 6.29B | C+ | ||
+11.76% | 6.26B | C | ||
+70.00% | 4.78B | C | ||
-1.17% | 4.7B | D- | ||
-5.58% | 4.03B | B | ||
-7.87% | 3.62B | C- | ||
-6.67% | 3.06B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.